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ABSTRACT
Background and Objectives: Udenafil, a new phosphodiesterase-5 inhibitor (PDE5i), has 
been used to treat erectile dysfunction. Given the proven benefit of PDE5i in pulmonary 
arterial hypertension (PAH), we evaluated serial hemodynamic changes after single udenafil 
administration to determine the appropriate therapeutic dose.
Methods: Eighteen patients were randomly allocated into one of 3 groups: placebo, udenafil 
50 mg (U50), and udenafil 100 mg (U100). Diagnosis for inclusion was idiopathic PAH or 
PAH associated with connective tissue disease. Patients with any contraindication to PDE5i, 
and/or PDE5i treatment in the past 1 month were excluded. Continuous hemodynamic 
monitoring was performed by placing a Swan-Ganz catheter. Information on cardiac index 
(CI), mean pulmonary arterial pressure (mPAP), mean systemic arterial pressure (mSAP), 
pulmonary arterial wedge pressure (PAWP), and pulmonary vascular resistance index (PVRI) 
was obtained for 4 hours after drug administration.
Results: The mPAP significantly decreased in both the U50 and U100 (−11 mmHg and −8 
mmHg from baseline, respectively, p<0.1). The mSAP also decreased in both U50 and U100; 
however, the decrease was greater in the U100 (Δ=−8.5 mmHg and Δ=−14.0 mmHg). CI 
increased in the U50, but decreased in the U100. Although PVRI decreased in both, statistical 
significance was only achieved in the U50 compared to placebo. PAWP was stable during 
monitoring. U50 had at least 4 hour-effect after administration. Only 2 patients with U100 
experienced mild adverse events.
Conclusions: This is the first demonstration of the acute hemodynamic changes induced 
by udenafil. U50 is considered an optimal dose for treating PAH with more than 4-hour 
treatment effect.
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INTRODUCTION
Udenafil (Zydena®; Dong-A ST, Seoul, Korea) is a drug within the phosphodiesterase-5 
inhibitor (PDE5i) class. Similar to other PDE5i drugs, udenafil has been developed for erectile 
dysfunction and is approved in Asia with single dosages of 50, 100, and 200 mg. There have 
been personal reports of off-label use of udenafil for pulmonary arterial hypertension (PAH), 
and udenafil has a theoretical background of pulmonary vasodilator effect as a member of 
the PDE5i class. Furthermore, udenafil has a longer half-life (10–13 hours) than sildenafil 
and has a rapid onset of action (peak plasma concentration 1–2 hours after administration); 
thus, drug usage twice per day is possible. However, acute hemodynamic response and 
optimal dosage for patients with PAH has not yet been evaluated. We investigated the acute 
hemodynamic impact of udenafil on pulmonary and systemic circulation and determine the 
optimal dosage for a phase IIb study.
METHODS
Patient population
Patients (age ≥18 years) who were diagnosed with idiopathic PAH or PAH associated with 
connective tissue disease with symptoms (New York Heart Association [NYHA] functional 
class II–IV) were included. At baseline right heart catheterization, all patients met the 
following hemodynamic criteria for inclusion; mean pulmonary arterial pressure (mPAP) 
≥25 mmHg, PVR ≥400 dyne/sec/cm−5, and pulmonary artery wedge pressure (PAWP) or left 
ventricular end diastolic pressure ≤15 mmHg.
All patients should have maintained their medication for the last 30 days and endothelin 
receptor antagonist (ERA) dosage should not be changed for 12 weeks before the screening test.
Exclusion criteria was as follows: 1) expected survival less than 6 months, 2) body mass 
index less than 18.5 kg/m2, 3) HIV infection, 4) recent myocardial infarction, cerebral 
infarction, and life threatening arrhythmia within 6 months before screening, 5) history 
of atrial septostomy or angina within 12 weeks of screening, 6) left ventricular ejection 
fraction less than 45% or any left ventricular outflow tract obstruction or aortic stenosis 
at screening echocardiography, 7) abnormal liver function test (3 times higher aspartate 
aminotransferase/alanine aminotransferase level than normal range), 8) hypotension 
less than 90/50 mmHg or uncontrolled hypertension greater than 170/100 mmHg, 9) 
severe lung disease (total lung capacity less than 70%), 10) severe renal or moderate to 
severe liver disease, 11) history of non-arteritic anterior ischemic optic neuropathy, 12) 
pregnancy, peripartum, or breast-feeding woman, 13) Corrected QT prolongation on 
electrocardiogram, 14) history of hypersensitivity to PDE5i, 15) drugs or diet that can affect 
udenafil metabolism such as antibacterials, antifungals, antiviral agent, cimetidine, and 
grapefruit juice.
The Institutional Review Board of each institute (1105-039-361 at Seoul National University 
Hospital; 2011-05-037 at Samsung Medical Center; 4-2011-0343 at Yonsei Severance Hospital) 
and regulatory authorities approved the study protocol, and written informed consent was 
obtained from all participants. The Ministry of Food and Drug Safety in Korea approved the 
use of udenafil in patients with PAH for this study.
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Study protocol
After screening, study subjects (n=18) were randomly allocated to udenafil 50 mg (U50), 
udenafil 100 mg (U100), or placebo groups. There were 6 subjects in each group. Swan-Ganz 
catheters were inserted through the internal jugular vein, and baseline hemodynamics were 
evaluated. After initial assessment, undenafil or placebo was administrated to all patients. 
Hemodynamic monitoring was maintained for 4 hours and hemodynamics were repeatedly 
assessed at 30, 60, 90, 120, 180, and 240 minutes after drug administration.
Hemodynamic evaluation
Major hemodynamic parameters for drug response were evaluated as follows: pulmonary 
vascular resistance index (PVRI), pulmonary vascular resistance (PVR), cardiac index (CI), 
and cardiac output (CO). Standard thermodilution technique was used to estimate CO, and 
CI was calculated by multiplying CO by heart rate (HR). Additional hemodynamic parameters 
were acquired from continuous monitoring from Swan-Ganz catheters and a-line monitoring 
as follows: mPAP, systolic pulmonary arterial pressure, diastolic pulmonary arterial pressure, 
systemic vascular resistance index, systemic vascular resistance, mean systemic arterial 
pressure (mSAP), systolic systemic arterial pressure, diastolic systemic arterial pressure, 
PAWP, right atrial pressure, central venous pressure, HR, mixed venous oxygen saturation, 
partial pressure of arterial oxygen, partial pressure of carbon dioxide, and oxygen saturation.
Adverse events, adverse drug reactions, and serious adverse events were monitored 
throughout the study by the attending physician.
Data analysis
This was an exploratory clinical trial to determine the dose of udenafil for PAH, and formal 
sample size calculations were not conducted. Considering a drop-out rate of 15%, a total of 
18 patients (or 6 patients in each group) was the target number of subjects.
Demographics, baseline characteristics, hemodynamic variables, and gas exchange 
variables were summarized by treatment group and all subjects. Demographics and baseline 
characteristics were summarized with descriptive statistics as mean±standard deviation for 
continuous variables and frequency for categorical variables. Also, hemodynamic parameters 
were described with median and quartiles as (Q1, Q3).
This study enrolled fewer subjects and nonparametric methods were used. Wilcoxon signed 
rank test was conducted at a significance level of 0.1 to compare the maximal decrease 
from baseline within each treatment group. In addition, Page's trend test was conducted to 
confirm increasing the tendency for change from baseline CI in the U50 group.
All statistical analyses were performed using SAS version 9.1 (SAS Institute Inc., Cary, NC, 
USA) and R software version 3.2.3 (R Foundation, Vienna, Austria).
RESULTS
Eighteen patients (6 patients per group) were finally included and analyzed. Characteristics 
of study subjects and baseline hemodynamic parameters are described in Table 1. Mean age 
was 40, and 78% of all patients were female. According to the NYHA functional classification, 
56% of patients were in functional class II and 44% of patients were in functional class III. ERA 
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medication was already given in 72% of the patients. The etiology of PAH was idiopathic in 61% of 
patients and the rest were PAH associated with connective tissues disease. The mPAP was markedly 
elevated (52.0 mmHg; 38.0, 58.0), and mSAP was normal. CI was in the lower normal range (2.95 
L/min/m2) with a correspondingly increased PVRI (PVRI, 1,182 dyne/sec/cm−5/m−2; 679, 2,150).
Hemodynamic changes after udenafil administration
Hemodynamic monitoring showed decreased mPAP after udenafil administration with a 
single dose of both 50 and 100 mg (Figure 1A). Maximal mPAP reduction during 4 hours of 
monitoring was 11.0 mmHg in the U50 group and 8.0 mmHg in the U100 group. However, 
PVRI decreased only in the U50 group (MaxDiff=−511 dyne/sec/cm−5/m−2) and the U100 and 
placebo groups did not show a significant change (MaxDiff=226 and −141 dyne/sec/cm−5/m−2) 
(Figure 1B). Change in mSAP was significant in the U100 group, with a maximal difference of 
14 mmHg, which is significantly lower than the baseline value. However, this was not true in 
the U50 group (Figure 1C). CI tended to increase in the U50 group (p<0.01) and there was no 
change in the placebo and U100 groups (p>0.05, both) (Figure 1D).
There were no serious adverse events during the study. Adverse events were observed in 
4 patients in the placebo group, no patients in the U50 group, and 2 patients in the U100 
group. Adverse events and adverse drug reactions are shown in Table 2.
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Table 1. Baseline hemodynamic and gas exchange variables
All (n=18) U50 group (n=6) U100 group (n=6) Placebo group (n=6)
Age (years) 40±14 36±18 49.00±13.61 36.17±6.11
Gender (women) 14 (78) 5 (83) 6 (100) 3 (50)
PAH cause
IPAH 11 (61.1) 5 (83.3) 2 (33.3) 4 (66.7)
CTD 7 (38.9) 1 (16.7) 4 (66.7) 2 (33.3)
NYHA functional class
Class II 10 (56) 1 (17) 3 (50) 6 (100)
Class III 8 (44) 5 (83) 3 (50) 0 (0)
ERA medication 13 (72) 4 (67) 4 (67) 5 (83)
HR (beats/min) 74 (62, 82) 83 (58, 94) 65 (62, 74) 74 (67, 76)
mSAP (mmHg) 84.5 (78.0, 88.0) 84.0 (84.0, 88.0) 81.5 (74.0, 86.0) 87.0 (82.0, 96.0)
mPAP (mmHg) 52.0 (38.0, 58.0) 50.5 (43.0, 72.0) 47.0 (30.0, 57.0) 55.0 (49.0, 66.0)
CI (L/min/m2) 2.95 (1.79, 3.50) 2.21 (1.48, 3.03) 3.24 (2.71, 3.50) 3.18 (1.79, 3.65)
SVRI (dyne/sec/cm−5/m−2) 1,944 (1,733, 3,069) 2,968 (1,819, 3,070) 1,743 (1,606, 3,131) 1,945 (1,733, 2,959)
PVRI (dyne/sec/cm−5/m−2) 1,182 (679, 2,150) 1,521 (738, 3,237) 887 (575, 1,187) 1,213 (1,098, 2,150)
MVO2 78.6 (68.2, 83.1) 77.9 (71.0, 85.3) 67.2 (65.0, 79.8) 82.3 (77.4, 88.0)
PaO2 (mmHg) 73.8 (68.7, 91.6) 81.8 (72.0, 91.6) 72.9 (60.0, 79.0) 70.0 (67.1, 94.6)
Data are presented as mean±standard deviation or number (%), or median value with quartiles (Q1, Q3).
CI = cardiac index; CTD = connective tissue disease; ERA = endothelin-receptor antagonist; HR = heart rate; IPAH = idiopathic pulmonary arterial hypertension; 
mPAP = mean pulmonary arterial pressure; mSAP = mean systemic arterial pressure; MVO2 = mixed venous oxygen saturation; NYHA = New York Heart 
Association; PAH = pulmonary arterial hypertension; PaO2 = partial pressure of arterial oxygen; PVRI = pulmonary vascular resistance index; SVRI = systemic 
vascular resistance index; U50 = udenafil 50 mg; U100 = udenafil 100 mg.
Table 2. Adverse event and adverse drug reaction
Placebo U50 U100
No. of subjects No. of events No. of subjects No. of events No. of subjects No. of events
Adverse event 4 Mild 8 0 Mild 0 2 Mild 2
Moderate 1 Moderate 0 Moderate 2
Severe 0 Severe 0 Severe 0
Adverse drug reaction 0 Mild 0 0 Mild 0 1 Mild 2
Moderate 0 Moderate 0 Moderate 0
Severe 0 Severe 0 Severe 0
Serious adverse event 0 0 0 0 0 0
U50 = udenafil 50 mg; U100 = udenafil 100 mg.
Of note, there were no adverse events or adverse drug reactions in the U50 group. Adverse 
events in the placebo group were procedure-related, such as puncture site pain. Adverse 
events in the U100 group were exclusively puncture-related, and 1 patient experienced the 
adverse drug reaction of mild fever, which was possibly related to udenafil.
DISCUSSION
Udenafil is a newly developed long-acting PDE5i with efficacy and safety profiles comparable 
with those of other PDE5i. Similar to other PDE5i, udenafil was originally developed for the 
treatment of erectile dysfunction.1) Udenafil has a longer half-life than sildenafil and shows 
persistent vasodilator effects for 12 hours after administration.2)3) Like other PDE5i, udenafil 
has been used for a variety of clinical applications for important disease entities, including 
left ventricular hypertrophy,4) heart failure,5) and portal hypertension.6)
Because sildenafil7) and tadalafil8) are already approved for PAH-specific treatment, the class 
effect of udenafil in this rare but clinically important disease has been anticipated. Because 
of delayed approval of sildenafil and tadalafil for PAH treatment by the Korean Food & Drug 
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Baseline 30 60 90 120 180 240 MaxDiff
Placebo (n=6) 55.0 0.5 0.0 −3.0 −2.5 −2.5 −3.0 −3.5
U50 (n=6) 50.5 0.0 −5.0 −5.0 −6.0 −6.5 −9.0 −11.0
U100 (n=6) 47.0 −1.5 −6.5 −6.5 −7.0 −5.5 −6.0 −8.0
Baseline 30 60 90 120 180 240 MaxDiff
Placebo (n=6) 1,213 34 −82 −49 −24 −46 17 −141
U50 (n=6) 1,521 −35 −337 −323 −479 −343 −509 −511
U100 (n=6) 887 −99 −107 −109 −126 −215 −116 −226
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Figure 1. Changes in major hemodynamic parameters according to time. (A) Change in mPAP from baseline. (B) Change in PVRI from baseline. (C) Change in 
mSAP from baseline. (D) Change in CI from baseline. 
CI = cardiac index; mPAP = mean pulmonary arterial pressure; mSAP = mean systemic arterial pressure; PVRI = pulmonary vascular resistance index; U50 = udenafil 
50 mg; U100 = udenafil 100 mg.
Administration, there have been off-label uses of udenafil for patients with PAH. Clinical 
experiences for PAH in Korea have been shared in a clinical working group. This study was 
designed to determine optimal dosage and administration intervals of udenafil in patients 
with PAH by demonstrating continuous hemodynamic monitoring data, which can be used 
for efficacy study of udenafil in PAH. Udenafil tablets are already available as 3 different 
types, i.e., 50, 100, and 200 mg, in clinical practice. Among the 3 different doses, the 50 and 
100 mg tablets were adopted for this study to investigate the basis of pharmacokinetics in 
patients with PAH, based on the earlier study performed in patients with heart failure.5)
In the current study, we found that mPAP was significantly and similarly decreased in both 
the U50 and U100 groups compared to the placebo group. This salutary effect started 1 
hour after udenafil administration and persisted for at least 4 hours. Of interest, PVRI was 
only decreased in the U50 group up to 511 dyne/sec/cm−5/m−2 compared to the baseline 
value, but a reduction in PVRI was not observed in U100, which only demonstrated a small 
decrease in PVRI. This observation should be considered together with serial changes in 
mSAP and CI; although mSAP decreased in both U50 and U100, the amount of reduction 
in the U100 group was greater than the corresponding value observed in the U50 group. 
More importantly, change of mSAP was even greater than that of mPAP in the U100 group. 
Of note, CI was significantly increased in U50, suggesting an immediate benefit in PAH 
hemodynamics. However, CI significantly decreased in U100 for 2 hours after administration 
of U100. This finding implies that 50 mg udenafil should be considered the optimal dose 
in PAH management rather than 100 mg as a single dosage. It is conceivable that mSAP 
was significantly decreased in U100 for the first 90 minutes after udenafil administration, 
possibly resulting in preload reduction in the right ventricle, and finally leading to decreased 
CO even though PVRI was decreased.
PDE5i is a potent vasodilator, and its selectivity for pulmonary circulation is an essential 
component when a new PDE5i is considered for PAH treatment. The acute hemodynamic 
effects of sildenafil, tadalafil, and vardenafil on pulmonary circulation in earlier studies9) were 
variable. In addition, there were variable effects in their kinetics of pulmonary vasorelaxation 
(most rapid effect by vardenafil), selectivity for pulmonary circulation (sildenafil and tadalafil, 
but not vardenafil), and impact on arterial oxygenation (improvement with sildenafil only). 
Currently, sildenafil and tadalafil have been approved for PAH treatment based on clinical 
evidence. Our study shows good selectivity of udenafil for pulmonary circulation at a dosage 
of 50 mg, resulting in pulmonary vasodilation without significant compromise of systemic 
circulation. Hemodynamic response to udenafil started an hour after udenafil administration 
and persisted for at least 4 hours. When we compared the study results with previous data 
published by using sildenafil, tadalafil, and vardenafil,9) a change in maximal PVRI was 
greatest with U50. This result suggests that udenafil has the highest selectivity for pulmonary 
circulation, although udenafil is similar to sildenafil in molecular structures and is comparable 
in terms of PDE5 selectivity10) (Figure 2). Considering the consistent and continuing 
reduction in mPAP and PVRI in the U50 group and the long half-life of udenafil,11)12) a 12-hour 
administration interval of U50 is possible and clinically relevant.
In this study, despite a small number of patients enrolled, we found only minor adverse 
drug reactions in the U100 group. Given a long half-life and only 2 administrations per day, 
patient compliance would be augmented with udenafil compared to sildenafil because daily 
medication frequency is generally accepted to exert a significant effect on patient compliance 
and potentially on prognosis.13)14)
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In conclusion, for the first time, we demonstrated the acute hemodynamic changes induced 
by udenafil in patients with PAH. PVRI reduction was greater in a 50 mg-dose of udenafil as 
compared to that in a 100 mg-dose of udenafil. CI did not decrease at most points and safety 
was excellent in the U50 group, suggesting that 50 mg udenafil is adequate for the phase 
progress of PAH clinical trials. This study lays the foundation for clinical trials with udenafil 
for PAH treatment.
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